Spike Pharmaceuticals Added New Product of Esomeprazole Sodium for Injection Approved


Release time:

2020-09-14

Spike Pharmaceutical Added New Products

Esomeprazole Sodium for Injection Approved

News from our newspaper  9Month3On the 1st, Jianfeng Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (batch number:2020S00572)。

Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017Year Edition), classified as Class B. According to industry statistics, the variety currently has Zhengda Tianqing, Qilu Pharmaceutical, etc.30two enterprises have been approved for listing in china,2019Annual domestic (including urban and county-level public hospitals, community and township health centers) sales of approximately33.17Billions of dollars.

Spike Pharmaceuticals in 2013Year11The application for registration of esomeprazole sodium for injection was submitted to the State Food and Drug Administration in January and accepted. Up to now, Peak Pharmaceuticals has invested nearly in research and development costs for the project.1500million, and already has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business.